Elopag 25 MG (Eltrombopag)

Basic Product Information of Elopag 25 (Eltrombopag) 25mg

How Elopag (Eltrombopag) Works

Elopag contains Eltrombopag, a small-molecule, orally bioavailable agonist of the thrombopoietin (TPO) receptor, also known as cMpl. Unlike natural thrombopoietin, Eltrombopag interacts with the transmembrane domain of the TPO receptor rather than the site used by the body’s own hormone, initiating signalling cascades that promote the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.

Because megakaryocytes are the cells responsible for producing platelets, activating this pathway increases platelet production and raises circulating platelet counts. This makes Elopag valuable in conditions where platelet counts are low due to immune destruction, viral infection-related effects, or bone marrow failure, helping to reduce the risk of bleeding and, in some cases, allowing other necessary treatments to proceed safely.

Elopag is taken as a once-daily oral tablet, with the dose individually titrated based on the patient’s platelet count response, and is not intended to normalise platelet counts to a “normal” range but rather to reduce bleeding risk to an acceptable level.

Indications for Elopag (Eltrombopag)

Elopag (Eltrombopag) is indicated for the following conditions:

Benefits of Elopag 25 (Eltrombopag) 25mg

How to Take Elopag (Eltrombopag)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Elopag treatment. Your physician will check liver function tests (ALT, AST, and bilirubin) before starting treatment, every 2 weeks during the dose adjustment phase, and monthly once a stable dose is established, with more frequent testing in patients receiving first-line therapy for severe aplastic anaemia. Monitoring also includes complete blood counts with platelet count, regularly during dose titration, peripheral blood smear examination for bone marrow changes, and periodic eye examinations, as TPO receptor agonists have been associated with cataract development in some studies. Report any yellowing of the skin or eyes, dark urine, unusual bleeding or bruising, or vision changes to your doctor immediately.

Drug Interactions and Important Information

Eltrombopag is extensively metabolised via CYP1A2 and CYP2C8 oxidation and UGT1A1/UGT1A3 glucuronidation, so caution is needed with medications that significantly affect these pathways. Eltrombopag also inhibits the OATP1B1 transporter and BCRP, which can significantly increase the plasma concentration of certain statins (such as rosuvastatin); a lower statin dose with careful monitoring is generally recommended when co-administered.

Elopag can chelate with polyvalent cations found in antacids, dairy products, and mineral supplements, significantly reducing its own absorption if taken too close together; maintain the recommended separation from these products. Inform your physician of any history of liver disease, blood clots, or eye conditions such as cataracts before starting treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Elopag.

Side Effects and Precautions

Who Should Use Elopag (Eltrombopag)?

Elopag is suitable for patients with chronic Immune Thrombocytopenia who have had an inadequate response to first-line treatments, patients with chronic Hepatitis C-associated thrombocytopenia who need platelet support to begin or continue antiviral therapy, and patients with severe aplastic anaemia, either as first-line combination therapy or after inadequate response to immunosuppressive treatment. It is prescribed by haematologists and hepatologists experienced in managing platelet disorders. A thorough medical assessment including baseline liver function, complete blood counts, and cardiovascular risk evaluation is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, haematology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Elopag under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Elopag is one of Everest’s specialty haematology products, offering a bioequivalent alternative to Promacta (Revolade) at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty medications. We ensure Elopag (Eltrombopag) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Elopag (Eltrombopag) from Mediaid Pharmacy?

Elopag represents a well-established, oral option for patients managing low platelet counts due to ITP, hepatitis C, or aplastic anaemia. As the generic equivalent of Promacta (Revolade), it delivers the same active ingredient, Eltrombopag, with the same proven TPO receptor agonist mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Elopag gives patients worldwide access to effective platelet-support therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Eltrombopag option with worldwide delivery, Elopag from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Elopag (Eltrombopag)